GO:0004799 thymidylate synthase activity: Mechanism, Genes

Thymidylate synthase activity (GO:0004799) is a molecular function that catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), using 5,10-methylenetetrahydrofolate as the methyl donor and generating 7,8-dihydrofolate as a byproduct. This reaction is the sole de novo source of dTMP in most organisms and is therefore indispensable for DNA synthesis, repair, and cell proliferation. Because rapidly dividing cells depend on a continuous supply of dTMP, thymidylate synthase (TS) has long been recognized as a central node in one-carbon metabolism and a prime target for antiproliferative and antimicrobial therapies [1,4]. The enzyme is encoded by the TYMS gene in humans and is the prototype of the classical thymidylate synthase family, while flavin-dependent thymidylate synthases (FDTS) found in some bacteria and archaea use a distinct mechanism [7,8]. In clinical oncology, thymidylate synthase activity is directly linked to the mechanism of action of fluoropyrimidines such as 5-fluorouracil and to folate-based inhibitors such as ZD1694 (Tomudex), which form stable ternary complexes with the enzyme and its cofactor. Expression levels of TYMS have been associated with diagnostic and prognostic outcomes in breast cancer, and inhibition of TYMS by metronomic capecitabine has been shown to trigger ferroptosis in hepatocellular carcinoma cells. These findings underscore the importance of GO:0004799 not only as a biochemical reaction but as a therapeutic vulnerability and a biomarker of drug response [1,2,3]. For researchers, GO:0004799 provides a precise functional annotation for genes and proteins involved in dTMP biosynthesis, enabling comparative genomics, structural biology, and drug discovery across species [5,6,7,8]. Understanding the catalytic mechanism, regulation, and disease relevance of thymidylate synthase activity is essential for developing next-generation inhibitors and for interpreting CRISPR-based functional screens that target one-carbon metabolism.

GO:0004799 thymidylate synthase activity is defined as the catalysis of the reaction: 5,10-methylenetetrahydrofolate + dUMP = 7,8-dihydrofolate + thymidylate. In other words, the enzyme transfers a methyl group from 5,10-methylenetetrahydrofolate to dUMP, reducing it to dTMP while oxidizing the folate cofactor to dihydrofolate. This activity is synonymous with dTMP synthase activity, TMP synthetase activity, and methylenetetrahydrofolate:dUMP C-methyltransferase activity.

Thymidylate synthase activity is essential for DNA replication and repair because it provides the only de novo source of dTMP, making it indispensable for cell division. Its central role in nucleotide metabolism has made it a major target for anticancer drugs such as 5-fluorouracil and raltitrexed, and for antimicrobial agents against pathogens like Cryptosporidium and Mycobacterium tuberculosis [1,5,8]. Moreover, TYMS expression levels are used as diagnostic and prognostic markers in breast cancer, and inhibition of TYMS can trigger ferroptosis in hepatocellular carcinoma. Thus, GO:0004799 is not only a fundamental biochemical activity but also a clinically actionable node in oncology and infectious disease.

The following genes and proteins are directly associated with thymidylate synthase activity (GO:0004799) or its regulation.

Thymidylate synthase activity is regulated at multiple levels. Transcription of TYMS is cell-cycle dependent, peaking during S phase via E2F1 and other proliferation-associated transcription factors. The enzyme is also subject to feedback inhibition by its product dTMP and by polyglutamated folates, which modulate substrate affinity. Additionally, TYMS mRNA translation is autoregulated by the enzyme itself, which binds to its own mRNA and represses translation when in excess. Post-translational modifications and protein-protein interactions further fine-tune TS activity in response to DNA damage and metabolic stress.

Colorectal cancer cells depend on thymidylate synthase activity for DNA replication, and inhibitors such as ZD1694 (Tomudex) have shown clinical activity in this disease. High TYMS expression is associated with resistance to 5-fluorouracil, making it a key determinant of chemotherapy response. Targeting TS remains a cornerstone of colorectal cancer treatment.

TYMS expression has diagnostic and prognostic value in breast cancer, with elevated levels correlating with poor clinical outcomes. Assessment of TYMS expression may help stratify patients for antifolate therapy. The enzyme is therefore both a biomarker and a therapeutic target in breast cancer.

Metronomic capecitabine inhibits TYMS and triggers ferroptosis in hepatocellular carcinoma cells, revealing a novel mechanism linking nucleotide metabolism to iron-dependent cell death. This suggests that TYMS inhibition could be exploited to induce ferroptosis in liver cancer. The study highlights the potential of targeting thymidylate synthase activity in hepatocellular carcinoma.

Flavin-dependent thymidylate synthases in pathogens such as Mycobacterium tuberculosis and Cryptosporidium are attractive drug targets because they differ structurally from human TS [5,8]. Inhibitors designed against these enzymes could provide selective antimicrobial therapy [5,8]. The unique mechanism of FDTS offers opportunities for species-specific inhibition.

Direct measurement of TS activity uses spectrophotometric or radiometric assays that monitor the conversion of dUMP to dTMP or the oxidation of 5,10-methylenetetrahydrofolate to dihydrofolate. These assays are essential for characterizing inhibitors and mutant enzymes.

TYMS mRNA levels can be quantified by RNA-seq or qPCR to assess transcriptional regulation and as a prognostic biomarker in breast cancer. These methods are widely used in clinical and research settings.

Western blotting and mass spectrometry can measure TS protein levels and post-translational modifications, providing insight into regulation and drug response. Proteomic profiling of one-carbon enzymes reveals pathway rewiring.

Genome-wide CRISPR knockout screens can identify genes that modulate sensitivity to TS inhibitors, uncovering synthetic lethal interactions [1,3]. Such screens are powerful for target discovery in cancer and infectious disease.

Researchers studying thymidylate synthase activity-related genes often need to determine whether a candidate gene is causally involved in dTMP synthesis, drug response, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models for functional validation.

Thymidylate synthase activity (GO:0004799) is a fundamental molecular function that sustains DNA synthesis and is a validated target in cancer and infectious disease. Its central role in one-carbon metabolism and drug response makes it a focal point for therapeutic development and biomarker discovery [1,2,3,4]. Understanding its mechanism, regulation, and disease associations provides a foundation for innovative research and clinical applications [5,6,7,8].